Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream

• Published in: International journal of dermatology Vol. 45; no. 5; pp. 600 - 604
• Main Authors: Repiso Montero, Trinidad, López, Sara, Rodríguez, Carmen, Del Rio, Ruben, Badell, Anna, Gratacós, M. Rosa
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.05.2006; Blackwell Science
• Subjects: Administration, Cutaneous; Adult; Antifungal Agents - administration & dosage; Antifungal Agents - therapeutic use; Biological and medical sciences; Cycloheptanes - administration & dosage; Cycloheptanes - therapeutic use; Dermatology; Dermatomycoses - drug therapy; Dermatomycoses - pathology; Double-Blind Method; Female; Human mycoses; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Infectious diseases; Male; Medical sciences; Miconazole - administration & dosage; Miconazole - therapeutic use; Middle Aged; Mycoses; Mycoses of the skin; Severity of Illness Index; Spain; Treatment Outcome; Spain; Human; Imidazole derivatives; Skin disease; Mycosis; Dermatology; Cream; Light peptide chain; Infection; Antifungal agent; Chemotherapy; Treatment; Double blind study; Eberconazole; Skin; Miconazole; Dermatophyte; Comparative study
• ISSN: 0011-9059; 1365-4632
• DOI: 10.1111/j.1365-4632.2006.02841.x

Background  Eberconazole is a topical, broad‐spectrum imidazole derivative, effective in dermatophytoses, candidiasis, and pityriasis treatment. In previous trials, it showed a higher efficacy than clotrimazole in the treatment of dermatophytoses. The purpose of this trial was to evaluate the efficacy of eberconazole 1% cream compared with miconazole 2% cream in the treatment of dermatophytoses. Methods  A multicenter, double‐blind, randomized trial was performed in 653 patients with dermatophytoses, randomized to eberconazole 1% cream every 12 h or miconazole 2% cream every 12 h for 4 weeks. Treatment efficacy was assessed on the basis of the percentage of effective response after 4 weeks through mycologic and clinical assessment. Results  Of the 653 patients included in the trial, 360 produced positive baseline mycologic cultures and were included in the efficacy assessment. Clinical efficacy was shown in 76.1% of patients receiving eberconazole and in 75.0% of patients receiving miconazole. The incidence of adverse events related to treatment was 0.91% for eberconazole and 0.92% for miconazole, none being serious, and all being local and transient. Conclusions  Eberconazole 1% cream is an effective treatment for fungal infections produced by dermatophytes, with a good safety and tolerability profile, and can be considered a good alternative for the treatment of dermatophytoses.